The new data, published in Journal of Clinical Investigation Insight, provides strong support for the development of the company’s FractalDx technology platform, and helps inform the design of a clinical validation programme (expected to commence in H2 2019) for an acute transplant rejection diagnostic as a follow-on product to KidneyIntelX™, the company’s AI-enabled diagnostic for fast-progressing chronic kidney disease. We look forward to further development updates with interest, and reiterat ....
07 Jun 2019
New supportive data for FractalDx
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
New supportive data for FractalDx
Renalytix Plc (RENX:LON) | 25.5 -0.3 (-3.8%) | Mkt Cap: 32.2m
- Published:
07 Jun 2019 -
Author:
Jens Lindqvist -
Pages:
3
The new data, published in Journal of Clinical Investigation Insight, provides strong support for the development of the company’s FractalDx technology platform, and helps inform the design of a clinical validation programme (expected to commence in H2 2019) for an acute transplant rejection diagnostic as a follow-on product to KidneyIntelX™, the company’s AI-enabled diagnostic for fast-progressing chronic kidney disease. We look forward to further development updates with interest, and reiterat ....